Sino Biopharmaceutical (HKSE:01177) Marketable Securities : HK$5,104 Mil (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Sino Biopharmaceutical's Marketable Securities for the quarter that ended in Dec. 2023 was HK$5,104 Mil.

Sino Biopharmaceutical's annual Marketable Securities declined from Dec. 2021 (HK$6,398 Mil) to Dec. 2022 (HK$5,422 Mil) and declined from Dec. 2022 (HK$5,422 Mil) to Dec. 2023 (HK$5,104 Mil).

Sino Biopharmaceutical Marketable Securities Historical Data

The historical data trend for Sino Biopharmaceutical's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Marketable Securities Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

8,005.51

6,131.93

6,398.14

5,422.15

5,103.90

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Marketable Securities	Get a 7-Day Free Trial															6,398.14	9,268.03	5,422.15	4,483.64	5,103.90

Sino Biopharmaceutical Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Sino Biopharmaceutical (HKSE:01177) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Sino Biopharmaceutical Marketable Securities Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical (HKSE:01177) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

SBHMY:USA SBMFF:USA SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (HKSE:01177) Headlines

No Headlines